Oculis Holding AG (OCS) Change in Interest Receivables (2024 - 2026)
Oculis Holding AG's (OCS) quarterly Change in Interest Receivables came in at -$266894.0 in Q1 2026, up 20.28% year-on-year from -$221894.7 in Q1 2025, and down 115.4% quarter-over-quarter from $1.7 million in Q4 2025.
Oculis Holding AG (OCS) Change in Interest Receivables (2024 - 2026) Analysis & Trends
Oculis Holding AG's Change in Interest Receivables history runs 3 years deep, the most recent figure standing at -$266894.0 for Q1 2026.
- On a quarterly basis, Change in Interest Receivables rose 20.28% year-over-year to -$266894.0 in Q1 2026; TTM through Mar 2026 was $862685.0, a 6.24% increase from a year earlier, with the FY2025 full-year figure at $715234.2, down 14.62% from the prior year.
- Change in Interest Receivables retreated to -$266894.0 in Q1 2026 per OCS's latest filing, from $1.7 million in the prior quarter.
- Across five years, Change in Interest Receivables topped out at $1.7 million in Q4 2025 and bottomed at -$334787.4 in Q1 2025.
- The 3-year median for Change in Interest Receivables is -$270919.4 (2024), against an average of $152724.0.
- Across the five-year window, Change in Interest Receivables sank 41.68% in 2025 and advanced 20.28% in 2026, its largest moves.
- Year by year, Change in Interest Receivables stood at $1.6 million in 2024, then gained by 6.23% to $1.7 million in 2025, then slumped by 115.4% to -$266894.0 in 2026.
- Per Business Quant, the three latest OCS Change in Interest Receivables figures stand at -$266894.0 (Q1 2026), $1.7 million (Q4 2025), and -$302526.5 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -266,893.98 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -266,893.98 |
| Dec 31, 2025 | 1.73 Mn |
| Sep 30, 2025 | -302,526.50 |
| Jun 30, 2025 | -300,764.67 |
| Mar 31, 2025 | -334,787.41 |
| Dec 31, 2024 | 1.63 Mn |
| Sep 30, 2024 | -213,528.34 |
| Jun 30, 2024 | -270,919.40 |
| Mar 31, 2024 | -300,168.77 |